Gilead Sciences and Galapagos NV receive complete response letter from FDA for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest